<?xml version="1.0" encoding="UTF-8"?>
<p id="Par29">
 <list list-type="order">
  <list-item>
   <p id="Par30">Patients who received any other study drug or participated in another clinical trial with therapeutic intention within 28 days before enrollment;</p>
  </list-item>
  <list-item>
   <p id="Par31">Patients have postoperative complications that require clinical intervention and affect treatment, such as gastroparesis, dumping syndrome, etc.;</p>
  </list-item>
  <list-item>
   <p id="Par32">Patients known to be allergic or intolerant to the study drugs;</p>
  </list-item>
  <list-item>
   <p id="Par33">Uncontrolled serious medical conditions that the investigator believes will affect the subject's treatment regimen, such as a combination of serious medical conditions, including severe heart disease (New York Heart Association (NYHA) level II or more severe congestive heart failure), cerebrovascular disease, uncontrolled diabetes, uncontrolled high blood pressure, uncontrolled infection, etc.;</p>
  </list-item>
  <list-item>
   <p id="Par34">Known history of HIV;</p>
  </list-item>
  <list-item>
   <p id="Par35">Known active HCV and HBV infection.</p>
  </list-item>
  <list-item>
   <p id="Par36">Patients had a malignant tumor other than gastric cancer in the past 5 years (except for the current gastric cancer); if it meets all the following criteria, it is qualified: treatment of malignant tumors for cure, such as fully treated cervical carcinoma in situ, non-melanoma skin cancer, or localized prostate cancer after radical operation (PSA ≤10 ng/ml); and no signs of recurrence or metastasis were found according to the imaging results of follow-up and any disease-specific tumor markers;</p>
  </list-item>
  <list-item>
   <p id="Par37">Patients accompanied by dysphagia, complete or incomplete gastrointestinal obstruction, active gastrointestinal bleeding, or perforation;</p>
  </list-item>
  <list-item>
   <p id="Par38">Female patients during pregnancy or lactation, or subjects of childbearing age who refuse contraception;</p>
  </list-item>
  <list-item>
   <p id="Par39">Patients who were not suitable for the enrollment of this study judged by the investigator.</p>
  </list-item>
 </list>
</p>
